GlaxoSmithKline (GSK) and Adaptimmune said they will co-develop and co-commercialize Adaptimmune's lead clinical cancer program under a collaboration disclosed today. The collaboration could yield for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results